Kymab receives $9m R+D grant from Bill & Melinda Gates Foundation
The monoclonal antibody biopharmaceutical group Kymab announced today that it…
The monoclonal antibody biopharmaceutical group Kymab announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.